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Introduction 
Photodynamic therapy (PDT) is a relatively new treatment option in medicine 
including treating some types of cancers. PDT utilizes light to activate small molecules 
for treatment. Some of these molecules used as PDT agents are porphyrin derivatives. 
While PDT is currently being used in the fight against cancer, it has several limitations 
and is currently being used in conjunction with chemotherapy and/or radiation in order 
to be effective. This research focused on synthesizing a new zinc (II) porphyrin and 
incorporating a fluorescent sulfocycline and testing the compound on the MB 231 breast 
cancer cell line. 
Once the metallated porphyrin was synthesized and purified, IR, UV-vis, 
fluorescence, and NMR spectroscopies were run to characterize the compound. Once 
this data was collected, the compound was tested on the MB231 cell line. The MB231 
cell line is also referred to as triple negative breast cancer cells. After cells were treated 
with the metallated porphyrin an MTI assay was run to look at cell viability in both light 
and dark conditions. 
Along with the testing of the synthesized metallated porphyrin, research was 
done on how patient attitude has been shown to effect patient outcome. While looking at 
this, cancer patients were focused on. In order to increase the number of available 
cases, other diseases were looked at as well. 
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Background 
Photodynamic Therapy (PDT) 
Photodynamic therapy is a medical procedure that utilizes a photosensitive 
molecule and a light source that activates the molecule (Cole). This treatment is 
currently used to treat some kinds of cancers and even acne. Researchers began to 
look at photodynamic therapy in the 1960's after Lipson and Baldes discovered that 
neoplastic tissues that had been injected with a porphyrin mixture that was a 
photosensitizer would fluoresce under a black light (Cole). Schwartz had originally 
synthesized this compound and classified it as a hematoporphyrin (Cole). Once tested , 
it was discovered that th is hematoporphyrin had a higher affinity for and stronger 
phototoxicity for tumor cells than hematoporphyrins. Photofrin was the first FDA 
approved drug from this group, and it was approved for clinical use in the 1970's. This 
also led to multiple light sources being created that could deliver specific wavelengths of 
light to more centralized areas of the body. Further research led to more approvals of 
various POT's in the 1990's that could be used in the treatment of malignant and non-
malignant cancers. 
When looking at photodynamic therapy there are three major steps in the 
process (Cole). The first step is the application of the photosensitizer drug. The second 
step involves an incubation period that allows the photosensitizer drug to locate and 
imbed itself in the tumor tissue. The final step is to deliver the wavelength of light to the 
area that will activate the compound. 
How the photosensitizer drug is applied depends on what area of the body that 
the tumor in question is located. Typical ly, the drug will be injected into the bloodstream 
so it can travel through the bloodstream to reach the target tumor tissue ("Photodynamic 
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Therapy"). In other cases, the drug will be applied to the skin. Because of the 
composition of the blood, it is imperative that the drug be water-soluble. The 
photosensitizer drug is synthesized so it is able to locate specific cell markers (Huang et 
al., 2008). These markers need to be located on the tumor cells themselves or other 
cells that are throughout the tumor. This will enable the photosensitizer drug to embed 
itself throughout the tumor tissue. The photosensitizing drugs have some criteria that 
they should meet to be ideal (Huang et al., 2008). To be ideal, the photosensitizer 
should: be made of a commercially available and pure chemical, high photocytotoxicity 
but low dark cytotoxicity, good selectivity for tumor cells, a longer wavelength that will 
allow for deeper penetration of the light waves, be rapidly removed from the body, and 
have multiple administration routes. 
The incubation period is the second step of photodynamic therapy (Huang et al., 
2008). Depending on the photosensitizer drug administered and the composition of the 
tumor being targeted, the incubation period varies in time. The length of time for the 
incubation period is a critical component for success. The incubation period needs to be 
long enough for the maximum amount of the photosensitizer drug to be able to spread 
throughout the tumor but not so long that the drug begins to leave the body through 
natural processes. To determine the optimum incubation period of the photosensitizer, it 
must be ensured that the photosensitizer drug has fluorescence emission. When the 
photosensitizer drug has fluorescence emission, the progress of the embedding of the 
PDT agent into the tumor cells can be monitored in vivo. By measuring the incubation 
period in an in vivo scenario, the incubation period in a clinical setting can be estimated 
fairly accurately (Huang et al. , 2008). 
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Once the photosensitizer drug has incubated for an appropriate amount of time a 
light is administered to the affected area (Cole). This light source must be at the range 
that the photosensitizer drug will become activated at (Huang et al., 2008). In the 
beginning, these light sources were noncoherent. Noncoherent light sources are safe 
for the patient, cheap to use, and are easy to operate. Unfortunately, these light sources 
have "significant thermal effect, low light intensity, and difficulty in controlling light dose" 
(Huang, 2005). Recently these drawbacks have been overcome with the introduction of 
light sources using light emitting diode (LED). LED lights are beneficial because they 
are able to deliver the desired wavelength of light at a high energy level. Two photon 
excitation (TPE) is also a current option (Huang, 2005). TPE involves the "simultaneous 
absorption of two photons generated from ultrafast laser pulses of high flux in the near-
infrared region" (Huang et. al., 2008). TPE has been shown to be beneficial for deeper 
lesions and is able to be more precise with a smaller area. The most recent discovery 
has been that of the diode laser. These lasers are able to produce "high energy 
monochromatic light of a specific wavelength with a narrow bandwidth" (Huang et. al., 
2008). The last thing to consider when looking at the light application is whether the light 
should be administered superficially or interstitially. Light application mainly depends on 
the location of the tumor. Probes allow doctors to administer the light interstitially for 
esophageal cancers and others. 
Once the photosensitizer drug is activated it must have oxygen in the 
environment or there will not be any antitumor effects (Huang et. al., 2008). For this 
reason, tumors that are hypoxic don't usually respond to PDT. A huge obstacle that can 
be presented is when the PDT causes hypoxia in the tumor because of the rapid 
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oxygen depletion that can happen. Experiments have been conducted that look at the 
effect of hyper oxygenating the tumor environment (Huang et. al., 2008). The clinical 
results have not yet been reported. Oxygen changing from its triplet form to its singlet 
form is what causes free radical reactions within the tumor cells (Pilawa et. al. , 2006) . 
These free radical reactions then lead to the death of tumor cells. 
PDT has its drawbacks of course ("Photodynamic Therapy"). One of the main 
disadvantages is that the light source, no matter which of the many options you pick, 
can only reach so far. This is why only some tumors can even feasibly be treated with 
PDT based on where they are located in the body. Because of how precise the light 
placement has to be, PDT cannot be used on cancer that has spread and is in multiple 
areas throughout the body. Additionally, the photosensitizer drugs that can be used for 
PDT make the patient sensitive to all light for an amount of time after the drug is 
injected. This requires the patient to take extra precautions in light. 
Currently, PDT is used to treat many diseases. Actinic keratosis is one disease 
that PDT seems to help with, but it is very difficult to truly know how much PDT is 
helping with treating the disease because affected areas can clear up spontaneously 
without treatment (Huang, 2005). Actinic keratosis are dangerous because of their 
tendency to transform into squamous cell carcinomas. Although it is difficult to know if 
observed changes are solely due to PDT, many studies show a higher rate of 
disappearance of actinic keratosis when PDT is used as the treatment option. This was 
compared with placebo PDT treatments to account for spontaneous clear-ups. PDT is 
also used to treat squamous cell carcinomas. When treating squamous cell carcinomas, 
cryotherapy is an option. PDT has been shown to show significantly Jess scarring 
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compared to cryotherapy. On top of this, PDT was shown to be more effective and 
achieve quicker results than cryotherapy. PDT is also considered when the surgical 
removal of the affected areas would result in death. PDT has also shown promise in 
treating basal cell carcinomas. PDT is typically recommended for basal cell carcinomas 
that are superficial or very thin. Cutaneous T cell lymphoma can also be treated with 
PDT. Like the other diseases mentioned, examination of location and thickness are 
determining factors for if this treatment is a viable option. PDT is also used to treat wet 
macular degeneration. Macular degeneration can either be wet or dry ("Wet Macular 
Degeneration"). Wet macular degeneration is much more severe and only accounts for 
10-15% of cases. It is usually caused by fluid or blood leaking into the macula which is a 
part of the retina that is responsible for central vision ("Wet Macular Degeneration"). 
PDT closes the abnormal blood vessels when it is activated. 
For this research, the end metallated porphyrin azide can be found in the figure 
below. 
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Fluorescence Versus Phosphorescence 
Fluorescence and phosphorescence are very closely related. There is one major 
difference between the two concerning the length of emission radiation 
("Phosphorescence"). Phosphorescent molecules are able to emit light for a longer 
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amount of time because they emit light at a lower metastable state compared to 
fluorescence. Fluorescence emits light almost immediately once excited. 
Phosphorescence molecules are typically solid materials that have a crystalline 
structure ("Phosphorescence"). This structure allows for the conservation of energy that 
allows the molecules to stay in the metastable state that they emit light in. This is part of 
the reason why phosphorescence is used when making things like emergency exit 
signs. Phosphorescent paints are so strong that they can be painted on all of the walls 
of an underground room and will continue to glow for several minutes after all of the 
lights go out and the walls will glow for several minutes. The amount of light given off 
after it has absorbed excitation radiation and the amount of absorbed excitation 
radiation are directly linked. 
Fluorescence is a subcategory of cold-light emission ("F:Iuorescence"). Once a 
fluorescent molecule has absorbed electromagnetic radiation it goes to a high energy 
state. Once it falls from this energy state back to the ground state, a photon is released 
and a light is observed. When looking at the emission radiation that is given off when 
this happens, it is always longer than the excitation radiation. This shows that the 
emission radiation has less energy than the excitation radiation. Fluorescent molecules 
contain alternating covalent single and double bonds. This system of alternating single 
and double covalent bonds can be seen in the metallated zinc porphyrin. Although 
fluorescent molecules do not retain the energy for as long as phosphorescent 
molecules, they are still used in several different areas. Fluorescence is seen in energy 
saving lamps and observed in special dye molecules. As a special dye, it can be added 
onto special documents like banknotes to make it harder for forging. 
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In this research, the metallated porphyrin and azide product fluoresce when 
exposed to a 365 nm light as shown by the figures below. 
Figure 2. Final product in white light. 
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Figure 3. Final product exposed to light of 365. 
Porphyrin 
Porphyrins can be described as "highly coloured cyclic tetrapyrrolic pigments 
formed by the linkage of four pyrrole rings through methene bridges" (Rastog i, 2006). 
Porphyrins are insensitive to steric hindrance which means it reacts well to having bulky 
side groups added to it. Porphyrins can also be metallated. Zinc is a great option for this 
because it is easy to insert but it also easy to remove. The zinc, or whatever metal is 
used, allows the porphyrin to retain fluorescence and singlet oxygen production . The 
retention of fluorescence and singlet oxygen production is critical when porphyrins are 
used in photodynamic therapy. Below is an example of the starting porphyrin used in 
this research with and without the zinc core. 
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H"'-. 
c~ ~c 
Click Chemistry 
Zn(0Ac)2 
DMF 
Figure 4. 
Click chemistry describes reactions that are "high yielding, wide in scope, create 
only byproducts that can be removed without chromatography, are stereospecific, 
simple to perform, and can be conducted in easily removable or benign solvents" ("Click 
Chemistry). It is a relatively new process that was coined by K.B. Sharpless in 2001 
("Click Chemistry"). Click chemistry is used in reactions such as cycloadditions, 
nucleophilic ring openings, carbonyl chemistry of the non-aldol type, and additions to 
carbon-carbon multiple bonds (Hein, 2008). 
When looking at click chemistry, there is one clear example that perfectly 
embodies the process. Copper-catalyzed azide-alkyne cycloaddition is this example. 
This type of click chemistry is especially useful when trying to add R groups to large 
molecules like porphyrins (Bryden). These reactions require a high temperature in order 
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to overcome the large activation energy. This is the type of reaction that was used in 
this research. The figure below (Figure 5) shows a simplified version of this type of click 
chemistry. 
N 
')/ + 
\\ 
NH 
azide 
Cu(l) 
.. 
alkyne triazole 
Figure 5. 
When looking at the metallated porphyrin that was used in this research, it is a 
large molecule. The azide that was added on is also a large molecule that is acting as 
the R group. In figure 6 below, the metallated porphyrin and azide are shown 
separately. This combination led to a very large ending molecule. As seen in the figure 
above (Figure 5), the combination forms an aromatic ring containing three nitrogen 
atoms. Coupling of the azide with the alkyne can be proven from various methods 
including NMR spectroscopy. 
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H 
5,10,15.20.tetrakis(4-alkynylphenyl)porphyrinatozinc(ll} Sulfo-Cyanine7.5 azide 
Figure 6. 
MB231 Cell Line 
The MB231 cell line is the most commonly used breast cancer cell line in 
laboratory studies ("MDA-MB-231"). This cell line was isolated from a 51-year-old 
Caucasian woman's pleural effusion. This patient was diagnosed with metastatic 
mammary adenocarcinoma. An adenocarcinoma is a type of cancer that arises in a 
mucus secreting gland in the body ("Adenocarcinoma"). In this case, it was a mucus 
secreting gland found in epithelial breast tissue. 
The MB231 cell line can be identified because of how highly aggressive, 
invasive, and poorly differentiated ("MDA-MB-231"). All of these factors make this 
particular cell line very difficult to kill even in a laboratory setting. The invasiveness of 
this cell line comes from the proteolytic degeneration of the extracellular matrices of 
cells. The triple negative aspect of the name comes from the fact that it lacks estrogen 
receptors, progesterone receptors, and human epidermal growth factor 2 receptors. The 
lack of these receptors means that the presence of any of these hormones does not 
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affect the growth of this cancer. At first this sounds like a good characteristic. In reality, 
many cancer treatments focus on how depriving the cancer cells of some or all of these 
hormones can prevent the growth of the cancer. Since these hormones do not affect the 
success of the cancer, treatment options are limited . When working with this cell line in 
a laboratory setting, if these cells are killed off then whatever you are testing should 
have great success in killing many different types of cancer cells. 
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Procedures 
Porphyrin Synthesis 
To synthesize the starting porphyrin (H2TPP-4ET), 1.0 g of 4-ethylbenzaldehyde, 
0.5 mL of pyrrole, and 100 mL of propionic acid were mixed together in a 250 mL round 
bottom flask. The reaction was stirred under reflux for 2 hours. The reaction was then 
allowed to cool to room temperature. And then it was placed into a -20°C freezer 
overnight. This allowed crystallization to occur. After crystallization, vacuum filtration 
was performed to isolate the crystallized product. Hexanes was then used to wash the 
solid. The solid was allowed to air dry overnight. The solid was later purified by silica gel 
column chromatography using dichloromethane to separate out impurities from the 
porphyrin. This reaction is shown in Figure 7 below. 
H"' /H 
H c~ c#c 
I ~c 
c=o ~ 
~ 0 + 
c 
Ill 
c ~c c~ I c~ ~c (1) H / 
"' 
H H 
(2) (3) 
Figure 7. 
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Metallation of the Porphyrin 
The final amount of unmetallated porphyrin produced determines the amount of 
zinc acetate dehydrate that should be added. In this research, 0.5 g of the unmetallated 
porphyrin and 0.32 g of the zinc acetate dihydrate were used with an excess of DMF. 
The zinc acetate dihydrate, porphyrin, and an excess of DMF were placed in a 250 ml 
round bottom flask and left to reflux and stir for about 2 hours. Next, the mixture was 
cooled to room temperature and run through a silica gel column with using 
dichloromethane as the element. The product was then dried using a rotary evaporator. 
This reaction is shown below in Figure 8. 
H" c~ ~c 
Zn(0Ac)2 
DMf' 
Figure 8. 
Coupling of the Zn TPP-4ET with Sulfur-Cyanine 7.5 Azide 
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The zinc porphyrin ZnTPP-4ET (.0004 g) and .0005 g of the azide were added to 
1~ mL of THF in a 25 ml round bottom flask. The mixture was degassed in nitrogen for 
10 minutes. 0.005 g of CuS04 ·5H20 in 3251JL of H20 was added to 0.006 g of TBTA in 
3251JL of DMSO. This combined mixture was then added to 0.007 g of 
tertbutylhydroquinone in 325 !JL ofTHF. This mixture was shaken and added to the zinc 
porphyrin and azide mixture. The mixture was left to stir and heat in a 50 oc water bath 
overnight. The solution was then run through a silica gel column to purify using 
dichloromethane as the eluent. The purified material was isolated and characterized by 
IR, UV-vis, fluorescence, and NMR. 
Treatment of MB231 Cell Line 
The MB231 cell line was plated on 100 cm2 plates at 15,000 cells/cm2 • The cells 
were plated with growth serum medium. The cells were maintained and split for a few 
weeks before testing began. Once it was time for the experiment, the number of cells on 
each plate was calculated so the proper dilutions could be done to get to 2,000 cells/ 
well in 100 IJL liquid. The dilution was performed with serum-free growth medium. Two 
96-well plates were obtained and the cells were plated onto these. The two plates were 
covered in foil and placed in the incubator for two days to allow the cells to adhere. 
The liquid was aspirated out of the wells and replaced with different 
concentrations of the metallated porphyrin azide dissolved in DMSO and serum-free 
growth medium. The concentrations were 1 mg/IJL, 5 mg/IJL, 10 mg/IJL, 25 mg/IJL, 50 
mg/IJL, and 1 00 mg/IJL Other wells had pure DMSO dissolved in serum-free growth 
medium and some had just new serum-free growth serum added. 
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The next day the liquid was aspirated out of the wells and 100 IJI of serum-free 
growth medium was added. One of the plates was then exposed to light for 20 minutes 
while the other was placed back into the incubator with the foil. The plate that was 
exposed to light was also added to the incubator after the 20 minutes. The next day, the 
liquid was aspirated out of the wells and replaced with MTT solution. The plates were 
then placed on the Belly Dancer for 3 hours. An MTT assay was then run on both 
plates. 
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Results 
Ultraviolet Visible Spectroscopy 
UV-vis showed at what wavelength the metallated porphyrin azide is activated . 
Based on the results shown in the figure below, the compound has an absorption 
maxima at 424 nanometers. 
4· 
r'l 3$· 
3 
-
2.5 
"' .
2 
~ 
1 ~ 
1 
~5 
) 
3'0 ;oo 4no ~0 9'.19 I 700 d( ~~ ,o'oo fl~'ll(f!'~h , .. 
Figure 9. UV-vis results for the metallated porphyrin azide. 
UV-vis was also run to calculate the molar extinction coefficient. This value was 
needed in calculations to determine how much of the metallated porphyrin azide was 
needed to get to the desired 25 mM concentration for the stock solution for MTT Assay. 
The molar extinction coefficient is .004193 mM-1 em -1 at 424 nm. 
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Figure 10. 
The red line (Figure 1 0) is the non-diluted metallated porphyrin azide. The dark blue 
line is the 25 mM stock solution of the metallated porphyrin azide. The light blue line is 
the 1 0 mM stock solution of the metallated porphyrin azide. 
Fluorescence Spectroscopy 
Fluorescence results show that 373 nm with an excitation wavelength for the final 
coupled porphyrin azide product (Figure 1) produced an emission at 458 nm. The 
metallated porphyrin azide emitted at 650 nm at the same excitation wavelength of 373 
nm. These results show that the addition of the sulfur-cyanine 7.5 azide causes the 
metallated porphyrin to emit at a wavelength closer to the ultraviolet range. 
Nuclear Magnetic Resonance 
The NMR results showed that the metallated porphyrin and the azide did 
combine. This is shown by comparing the metallated porphyrin and the metallated 
porphyrin azide. When looking at the NMR of the metallated porphyrin in Figure 11, 
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there are signals that point towards the following structures being present TMS with the 
signal at 0, chloroform with the signal around 7, and benzene and pyrrole rings with the 
signals at 8. When looking at the metallated porphyrin azide in Figure 12, the above 
signals are present as well as the signal around 1 that shows the presence of triple 
bonds on alkene groups. The NMR for the metallated porphyrin azide in Figure 12 
shows signals that point to the same structures as with the metallated porphyrin . 
.. 
Figure 11. NMR of metallated porphyrin. 
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Figure 12. NMR of metallated porphyrin azide. 
MTT Assay 
The results of the MTT assay show that the metallated porphyrin azide is not 
apparently toxic to the cells at the concentrations investigated. This was demonstrated 
when the different concentrations on the plate not exposed to light had relatively the 
same cell viability as that of the plate exposed to the light in Figures 13 and 14. 
Unfortunately, the results also show that the light that the one plate was exposed to did 
not activate the metallated porphyrin azide. 
When performing an MTT assay, you can look at the plate and get an idea about 
cell viability. The darker the shade of purple, the more cell viability_ Looking at the two 
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plates this way, it looked as if the cell viability was the same as seen in Figures 13 and 
14. A plate reader was used to calculate true cell viability as seen in Figures 15 and 16. 
Figure 13. Plate that was not exposed to light. 
Figure 14. Plate that was exposed to light. 
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Light Plate 
I) 1 10 /.S 100 
Figure 15. MTT assay results from the plate exposed to light. The x-axis is the 
concentration of metallated porphyrin (in IJM) and the number on each bar is the 
cell viability percentage. 
Dark Plate 
0 3 10 100 
Figure 16. MTT assay results from plate not exposed to light. The x-axis is the 
concentration of metallated porphyrin (in IJM) and the number on each bar is the 
cell viability percentage. 
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Conclusion 
Based on results from examining the compound under UV light, running UV-vis, 
fluorescence, and NMR spectroscopies, the metallated porphyrin and azide did 
combine. However, the results of the MlT assay show that there was no true difference 
in celt viability between the two plates exposed to light or dark conditions or between the 
different concentrations. These results show that although the metallated porphyrin was 
able to combine with the azide, the two together were not an effective agent for PDT. If 
it was, the MTT assay would've shown less cell viability on the plate exposed to light 
because the light should've activated the porphyrin and led to cell death. The high levels 
of cell viability also shows that the metallated porphyrin azide is not toxic to the cells. 
In future research, I would suggest testing the two plates again in a similar 
fashion but using a different light source. When looking to see if the metallated 
porphyrin azide exhibited fluorescence, the compound is excited at a wavelength of 365 
nanometers. It would be beneficial to expose one of the plates to a light source that is at 
or close to this wavelength to examine cytotoxicity in an MlT assay. 
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Additional Research 
As was mentioned earlier, patient attitude towards treatment was examined and 
compared to treatment effectiveness. Before looking at the research, it was 
hypothesized that there should be a correlation between an optimistic attitude and 
better treatment outcomes. Looking at research, the results are inconclusive. 
There have been several studies performed on patients with various types of 
cancers. Many of these studies show a correlation between attitude and treatment 
effectiveness. Some studies, however, didn't show a correlation between attitude and 
treatment effectiveness but did show that positive attitudes helped with coping 
("Attitudes and Cancer"). In order to maintain these positive attitudes, patients took part 
in activities like group therapy with other people that had cancer diagnoses. These 
studies showed that therapy and relaxation could help with reducing distress. While it is 
disheartening to see from these studies that attitude didn't affect outcome, attitude can 
help with mental health. An improvement in mental health makes the duration of 
treatment more bearable and help quality of life. 
The studies that showed a correlation between attitude and outcome are less 
conclusive. In one of these studies, patients with more optimistic attitudes were less 
likely to be hospitalized for complications (Fischer). These complications were shown to 
lead to worse overall outcomes and lower survival rates. These results are less 
conclusive because it is hard to know what is the cause and what is the effect. One 
option is that these patients' attitudes are to blame for the level of effectiveness and the 
higher likelihood of a poor overall prognosis. A second option is that these patients had 
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bad attitudes because the treatment had an adverse effect that made them feel unwell. 
These adverse effects would lead to the poor outcome and the pessimistic attitude. 
Gathering data for this part of the research was difficult because of how 
contradictory the research studies are. For every study that found no correlation, there 
was another study that showed that there was one. The problem seemed to be that the 
sample sizes were small and seemed to be picked with some bias according to reviews 
of the research studies. In the future, more randomized studies would be beneficial to 
organize. In order to determine the effects, the studies should be longer in length and 
have qualified health professionals interview the patients and determine their mental 
state and attitude. These studies are important to do because if attitude can affect 
effectiveness, more work should be put into ensuring patients stay optimistic throughout 
treatment. If it is the case, this could lead to patients being able to have positive 
outcomes with less surgery and chemotherapy. 
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